FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC

FDA Approves Capivasertib Plus Abiraterone and Prednisone in PTEN-Deficient mHSPC

FDA Approval Extends Truqap Into PTEN-Deficient Prostate Cancer

On June 12, 2026, the FDA approved capivasertib in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer. This population was previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The indication targets patients whose tumors carry PTEN loss as detected by an FDA-approved test, establishing a biomarker-driven approach to patient selection in the prostate cancer space.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for prostate cancer, with capivasertib and Truqap most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Abiraterone Remains Tied to Prednisone or Prednisolone Dosing

Abiraterone acetate is approved only for use in combination with prednisone or prednisolone administered orally at a dose of 5 mg in the morning and evening. This requirement applies to the new combination therapy as well. The glucocorticoid co-medication remains a fixed component of abiraterone-based treatment regimens, and no change to this dosing standard accompanies the prostate cancer approval.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for prostate cancer. Expect implications for pricing, access, and launch sequencing.

Truqap Already Had a Biomarker-Selected Oncology Label

Capivasertib is indicated in combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations. The prostate cancer approval expands the drug's labeled indications to a second disease area. Both indications rely on biomarker selection to identify eligible patient populations, reflecting a consistent strategy around companion diagnostics and genetic testing to guide treatment assignment.

IntelligenceStrategic Takeaways▾

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer on June 12, 2026. Abiraterone acetate requires concurrent prednisone or prednisolone at 5 mg orally in the morning and evening , a regulatory requirement that applies unchanged to the new combination therapy. Capivasertib is also indicated in combination with fulve

Strategic Context for BD and Investor Tracking

The approval creates a regulatory catalyst for AstraZeneca's oncology portfolio and establishes capivasertib in a new disease indication. For BD teams and investors tracking the company's pipeline, this represents label expansion within an existing asset rather than a novel drug entry. The biomarker-defined nature of the indication—PTEN loss detection—will be central to clinical adoption and patient identification in practice. Stakeholders should monitor for final label details, real-world implementation of PTEN-based patient selection, and any additional FDA or company updates tied to the prostate cancer indication going forward.

IntelligenceEvidence Quality▾

Grounded in 2 regulatory sources and 1 peer-reviewed source.

Key Takeaways

• The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer on June 12, 2026.
• Abiraterone acetate requires concurrent prednisone or prednisolone at 5 mg orally in the morning and evening, a regulatory requirement that applies unchanged to the new combination therapy.
• Capivasertib is also indicated in combination with fulvestrant for HR-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN-alterations, making the prostate cancer approval a second labeled indication for the drug.

Frequently Asked Questions